Submucosal Tumor of IntestineEFTRNCT03608540
Endomina as an Aid for Endoscopic Full Thickness Resection
A study testing Endomina in people with Submucosal Tumor of Intestine, run by Erasme University Hospital at 1 site in Belgium.
Trial summary
The concept of natural orifice transluminal endoscopic surgery (NOTES) (1) has evolved to endoscopic full thickness resection (EFTR). It represents innovation in technique that allows endoscopists to advance further into the endoscopic surgical space. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Submucosal Tumor of Intestine
- What is being tested?
- Endomina
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4 participants
- Where
- 1 siteBelgium
- Study dates
- 9 Jul 2018to 25 Oct 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Lesion untreatable with standard technique.
- Age between 18-65 years;
- Must be able to comply with all study requirements for the duration of the study as outlined in the protocol. This includes complying with the visit schedule as well as study specific procedures such as: clinical assessment, endoscopy, radiography, as well as laboratory investigations;
- Must be able to understand and be willing to provide written informed consent;
- Must live within 75 km of the treatment site;
Who cannot join
- Achalasia and any other esophageal motility disorders (for upper GI lesion)
- Severe esophagitis (for upper GI lesion)
- Gastro-duodenal ulcer (for upper GI lesion)
- Severe renal, hepatic, pulmonary disease or cancer;
- GI stenosis or obstruction;
- Pregnancy, breastfeeding or willing to become pregnant in the coming 18 months;
Show all 9Show fewer
- Anticoagulant therapy;
- Impending gastric surgery 60 days post intervention (Upper GI);
- Currently participating in other study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Prospective Study to Evaluate the Safety and Feasibility of an Endoluminal-suturing Device (Endomina TM) as an Aid for Endoscopic Full Thickness Resection
The concept of natural orifice transluminal endoscopic surgery (NOTES) (1) has evolved to endoscopic full thickness resection (EFTR). It represents innovation in technique that allows endoscopists to advance further into the endoscopic surgical space. EFTR has transformed the ability to tackle subepithelial tumors (SETs) and early mucosal neoplasm that are not amenable to classic ESD technique, enhance the staging accuracies for marginal lesions, and even increase the diagnostic capabilities for infiltrative disorders. Thus far, multiple methods have been described to perform EFTR, including nonexposed and exposed techniques, with the closure occuring before resection or after resection, respectively (2). Early comparative studies show no difference between the two methods (3). However, the procedures themselves are limited by the current tools available and by described techniques to achieve resection.
Investigators are described here a novel non-exposed technique, with closure before resection, using the Endomina device.
- Conditions
- Submucosal Tumor of Intestine
- Being tested
- Endomina
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EndominaDevice
Suturing system with sutures apposition then bulging then cutting
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | Suturing system with suture apposition then bulging formation then cutting the lesion Receives: Device: Endomina |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of all Adverse Device Effects
Safety will be characterized by the incidence of all Adverse Device Effects
Measured: one year from procedure
Secondary outcomes (1)
R0 resection
R0 resection at histology
Measured: 1 month after resection
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Aug 2018
- Study start9 Jul 2018
- Primary completion25 Oct 2021
- Study completion25 Oct 2021
Why it stopped: Enrolment too slow
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Submucosal Tumor of IntestineStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 4 participants (actual)
Sponsor and investigators
- Lead sponsor
- Erasme University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03608540
- Sponsor's protocol ID
- P2018/263
- Acronym
- EFTR
- Status last verified
- Nov 2021
- First submitted
- 10 Jul 2018
- Last updated
- 24 Nov 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Study to Evaluate the Safety and Feasibility of an Endoluminal-suturing Device (Endomina TM) as an Aid for Endoscopic Full Thickness Resection
- ClinicalTrials.gov ID
- NCT03608540
- Acronym / sponsor ID
- EFTR / P2018/263
- Conditions
- Submucosal Tumor of Intestine
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Enrolment too slow
- Enrolment
- 4 participants (actual)
- Lead sponsor
- Erasme University HospitalUniversity, hospital or other
- Study start
- 9 Jul 2018 (actual)
- Primary completion
- 25 Oct 2021 (actual)
- Study completion
- 25 Oct 2021 (actual)
- First posted
- 1 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The concept of natural orifice transluminal endoscopic surgery (NOTES) (1) has evolved to endoscopic full thickness resection (EFTR). It represents innovation in technique that allows endoscopists to advance further into the endoscopic surgical space. EFTR has transformed the ability to tackle subepithelial tumors (SETs) and early mucosal neoplasm that are not amenable to classic ESD technique, enhance the staging accuracies for marginal lesions, and even increase the diagnostic capabilities for infiltrative disorders. Thus far, multiple methods have been described to perform EFTR, including nonexposed and exposed techniques, with the closure occuring before resection or after resection, respectively (2). Early comparative studies show no difference between the two methods (3). However, the procedures themselves are limited by the current tools available and by described techniques to achieve resection.
Investigators are described here a novel non-exposed technique, with closure before resection, using the Endomina device.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Device: EndominaSuturing system with suture apposition then bulging formation then cutting the lesion |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Lesion untreatable with standard technique.
- Age between 18-65 years;
- Must be able to comply with all study requirements for the duration of the study as outlined in the protocol. This includes complying with the visit schedule as well as study specific procedures such as: clinical assessment, endoscopy, radiography, as well as laboratory investigations;
- Must be able to understand and be willing to provide written informed consent;
- Must live within 75 km of the treatment site;
Key exclusion criteria (9 listed)
- Achalasia and any other esophageal motility disorders (for upper GI lesion)
- Severe esophagitis (for upper GI lesion)
- Gastro-duodenal ulcer (for upper GI lesion)
- Severe renal, hepatic, pulmonary disease or cancer;
- GI stenosis or obstruction;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EndominaSuturing system with sutures apposition then bulging then cutting | Device | Intervention |
Primary outcome
Incidence of all Adverse Device Effects
Time frame: one year from procedure
Safety will be characterized by the incidence of all Adverse Device Effects
1 secondary outcome
R0 resection
Time frame: 1 month after resection
Results and safety
The study was stopped early (reason given: Enrolment too slow). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Nov 2021.
- Individual participant dataSharing planned: No
Related trials for Submucosal Tumor of Intestine
RecruitingObservational study
Malignant Polyp Registry
Malignant Colorectal Polyp, Colorectal Cancer
Not yet recruitingObservational study
Follow-up After Oncological Resection by Endoscopic Colorectal ESD (Endoscopic Submucosal Dissection)
Colorectal Neoplasms
Not yet recruiting
Endoscopic (EID) Versus Surgical (TAMIS) Local Excision for Early Stage Rectal Cancer
Rectal Cancer Stage I
Not yet recruitingObservational study
Clinical Outcomes After EMR or ESD of Colorectal Neoplasms - A Multicenter Registry
Colorectal Cancer, Colorectal Neoplasms
RecruitingObservational study
A Novel Clinical Decision Support Tool to Predict Submucosal Invasive Cancer Within Large Non-Pedunculated Colorectal Polyps
Colorectal Neoplasms, Colonic Polyps
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Endomina in people with Submucosal Tumor of Intestine, run by Erasme University Hospital at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 24 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Enrolment too slow). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of all Adverse Device Effects (time frame: one year from procedure). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Nov 2021.